mbs303MBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) confuration to kill malnant B cells. This dose-escalation phase Ⅰ trial evaluated the safetyMBS303 Track lurus idaman pembalap drag, mengadu peruntungan kemenangan dengan MBS 303 nominal hadiah hingga 69juta rupiah!